CD274 and metabolic dysfunction-associated steatotic liver disease: This finding was validated in a further cohort of 118 patients with HCC who were treated with PD(L)1-targeted immunotherapy (patients with NAFLD n = 11; patients with other aetiologies n = 107) (Supplementary Table 10).